Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Stock Watcher's Thread / Pix of the Week (POW) -- Ignore unavailable to you. Want to Upgrade?

To: P.E. Allen who wrote (3460)	2/26/1999 8:58:00 AM
From: P.E. Allen	Read Replies (1) \| Respond to of 52051

Thursday February 25, 4:15 pm Eastern Time Company Press Release SOURCE: ImmunoGen, Inc. ImmunoGen, Inc. CEO Provides Background on Recent Corporate Achievements at BIO CEO & Investor Conference NEW YORK, Feb. 25 /PRNewswire/ -- Presenting at the Biotechnology Industry Organization (BIO) CEO & Investor conference today, Mitchel Sayare, Ph.D., Chairman and CEO of ImmunoGen, Inc. (Nasdaq: IMGN - news), discussed new preclinical data from studies of huN901-DM1, the Company's tumor activated prodrug (TAP) for small-cell lung cancer. In addition, Dr. Sayare reviewed ImmunoGen's recently announced exclusive license agreement with SmithKline Beecham Plc, London/SmithKline Beecham, Philadelphia (SmithKline) to jointly develop and commercialize the Company's lead anti-cancer TAP, huC242-DM1, potentially worth $45 million, exclusive of royalties. Dr. Sayare presented initial data from preclinical studies of huN901-DM1, which showed that the compound, at a dose well below the maximum-tolerated dose, cured mice of human small-cell lung cancer. In an effort to examine combinations of agents that use different mechanisms to attack cancer cells, ImmunoGen researchers used lower, non-curative doses of huN901-DM1, combined with the chemotherapeutic, paclitaxel. This combination completely eradicated human small-cell lung cancer tumors in mice. The results were a significant improvement over either low doses of huN901-DM1 or the maximum tolerated dose of paclitaxel alone, or the currently-used combination of cisplatin and etoposide. The synergistic effect of huN901-DM1 plus paclitaxel may represent a promising potential treatment modality for small cell lung cancer. ''These data, similar to the results seen in preclinical studies with huC242-DM1, are encouraging, and position huN901-DM1 as an exciting, potential candidate to treat this aggressive cancer. The combination study offers an opportunity to consider multiple drug combinations to eradicate this disease, as we move this compound toward the clinic,'' stated Mitchel Sayare, Ph.D., Chairman and CEO of ImmunoGen, Inc. ''ImmunoGen will continue to develop huN901-DM1 in-house for the near-term.'' On the subject of the Company's colorectal product, Dr. Sayare added: ''Our collaboration with SmithKline serves as an endorsement of the huC242-DM1 product candidate and of ImmunoGen's tumor activated prodrug approach to treating cancer. We look forward to collaborating with SmithKline, one of the world's leading healthcare companies, on the development of huC242-DM1. The agreement will dramatically accelerate the clinical progress of huC242-DM1 and will provide us the financial wherewithal to continue the development of ImmunoGen's portfolio of tumor activated prodrugs.'' ImmunoGen, Inc. develops innovative biopharmaceuticals, primarily for cancer treatment. The Company has created potent tumor activated prodrugs, consisting of toxins or drugs coupled to monoclonal antibodies, for delivery to and destruction of cancer cells. This press release includes forward-looking statements based on management's current expectations. Factors that could cause future results to differ materially from such expectations include, but are not limited to: the ability to secure future funding; the success of the Company's research strategy; the applicability of the discoveries made therein; the difficulties inherent in the development of pharmaceuticals, including uncertainties as to the timing and results of preclinical studies; uncertainty as to whether the Company's potential products will succeed in entering human clinical trials and uncertainty as to the results of such trials; uncertainty as to whether adequate reimbursement for these products will exist from government, private healthcare insurers and third-party payors; and the uncertainties as to the extent of future government regulation of the pharmaceutical business. SOURCE: ImmunoGen, Inc.

To: P.E. Allen who wrote (3460)	2/28/1999 5:58:00 PM
From: Francois Goelo	Read Replies (1) \| Respond to of 52051

P.E. Allen, Ref: PLRP (10.5cents), I talked to the CEO and took a position... In my opinion, PLRP appears grossly undervalued and, as a result of my phone conversation with the CEO, I took a substantial position in the Company. I am waiting on a number of documents, such as Business Plan, latest financials and updated earning projections to be sent to me, so that I can prepare a report for the thread. Please, in the meantime, read the following excerpt from their Web site: www.pacel.com, concerning their main product. Then, wonder if a total market capitalization of around 2 Millions is right for a Company with such a product and clients like NASA. Regards, F. Goelo + + + Visual Writer System is a suite of programs that provides a complete solution to improving business performance and reducing costs. The software meets the needs of the MIS organization to quickly and easily create electronic documents with data acquisition capabilities that meet consistent standards, while allowing in-line managers to control the content and format, and have the ability to modify the documents to meet today's ever changing environment. The Visual Writer System is a suite of programs, requiring no programming capabilities, that helps you develop, manage perform, analyze, and report all these functions electronically without increasing the workload of your MIS organization. The suite consists of Visual Builder, which provides the tools to design and assemble interactive electronic documents; Visual Manager provides single source management functions including review/approval, status reporting and final data review. The Visual Worker is the runtime program, and Visual Analyzer is the report writing, analytical, and graphical presentation program. The Visual Writer System capitalizes on built-in "Power-Smart Suite"TM to automatically perform numerous functions without any input or effort by the document developer. These include creating the database and data tables associated with that electronic document, automated display of data on a spreadsheet, automatic graphical presentation of the data, document control for accountability of usage, permission level security, and version control to ensure only the latest document used. The Visual Writer System programs are "Self-Aware". They allow you to download your electronic documents from the LAN system to a portable computer. The program automatically brings with it all the associated and reference materials, documents, drawings, and videos that go with the electronic document and sets up temporary locations, so that the document operates identical to the way it would on the LAN system. The programs talk to each other during uploading and downloading and update their respective databases and data tables. During uploading the program sends the data to the designated repository for review and, upon acceptance, populates the applicable database and data tables. Note: Should the associated document database ever be lost, the document will automatically recreate the database, search existing files and repopulate the data tables. The Visual Writer System treats Interactive Electronic Document creation in a way that speeds development time and reduces program modification and maintenance costs. Instead of employing expensive MIS personnel who utilize complex programming languages to automate specific tasks within a business transaction, Visual Writer System provides the tools for employees who are knowledgeable about their business and have basic word processing skills to create, fine-tune, add to, and modify documents as needed. In essence, the system makes the computer an extension of management and their workforce, and allows him/her to automate their processes without having to depend upon subcontracted professionals or internal entities outside their control. The "Power-Smart Suite"TM and "Self-Aware" program features perform the functions of a programmer and provide the flexibility to initiate actions, make changes to the information, the data and the process on screen and on-the-fly thereby increasing productivity. These Automated and Interactive Electronic Documents will be easy to use, developed by skilled but non-programmer type employees, and will capitalize on instant access to reference information and data. The availability of this information will improve quality and productivity through out the process.